List of Excipients in Branded Drug QULIPTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	QULIPTA	atogepant	0074-7095	CELLULOSE, MICROCRYSTALLINE	2035-01-30
AbbVie Inc	QULIPTA	atogepant	0074-7095	COPOVIDONE K25-31	2035-01-30
AbbVie Inc	QULIPTA	atogepant	0074-7095	CROSCARMELLOSE SODIUM	2035-01-30

QULIPTA Excipient Strategy and Commercial Opportunities for Atogepant

Last updated: September 7, 2026

QULIPTA (atogepant) is an oral, once-daily small-molecule CGRP receptor antagonist marketed by AbbVie for preventive treatment of migraine in adults. Its immediate-release tablet platform uses conventional solid-dose excipients, creating opportunities in formulation enhancement, alternative dosage forms, generic development, contract manufacturing, and specialty excipient supply. The largest commercial opportunities are likely to involve improved swallowability, dose flexibility, pediatric or adolescent delivery, and formulation robustness rather than a simple substitution of commodity excipients.

What is QULIPTA and how is it positioned commercially?

QULIPTA contains atogepant, an orally active calcitonin gene-related peptide receptor antagonist. The FDA approved QULIPTA in September 2021 for preventive treatment of episodic migraine in adults and expanded the indication to chronic migraine in 2023.[1,2]

Attribute	QULIPTA profile
Active ingredient	Atogepant
Drug class	Small-molecule CGRP receptor antagonist
Dosage form	Immediate-release oral tablet
Strengths	10 mg, 30 mg, 60 mg
Administration	Once daily
Initial FDA approval	September 28, 2021
Chronic migraine approval	2023
Sponsor	AbbVie Inc.
Primary competitors	Aimovig, Ajovy, Emgality, Nurtec ODT, Ubrelvy
Regulatory pathway	New drug application, not a biologic
Generic pathway	ANDA, subject to applicable patent and exclusivity barriers
Biosimilar exposure	None; atogepant is a small molecule

AbbVie reported QULIPTA net revenues of approximately $1.4 billion in 2024, reflecting rapid adoption in the preventive migraine market.[3] The product competes against injectable monoclonal antibodies and oral CGRP products. Its once-daily oral schedule gives it a commercial advantage among patients who prefer tablets over monthly or quarterly injections.

What excipients are used in QULIPTA tablets?

QULIPTA is an immediate-release, film-coated tablet. The FDA labeling identifies conventional excipient classes used to support tablet manufacture, mechanical strength, disintegration, glidant performance, lubrication, and film coating.[1]

Public labeling identifies excipient components including:

• Mannitol
• Microcrystalline cellulose
• Povidone
• Sodium starch glycolate
• Colloidal silicon dioxide
• Lubricant components
• Film-coating materials, including polymeric coating ingredients, plasticizer or opacifier components, and colorants depending on tablet strength

The precise quantitative formula, processing parameters, granulation conditions, particle-size distributions, and supplier specifications are not generally disclosed in the public prescribing information. Those variables can have material effects on dissolution, content uniformity, tablet hardness, friability, moisture sensitivity, and manufacturing yield.

What functional roles do the QULIPTA excipients perform?

Excipient class	Likely formulation function	Commercial relevance
Mannitol	Diluent, mouthfeel modifier, compactability aid	Supports lower-dose tablet manufacture and acceptable oral sensation
Microcrystalline cellulose	Diluent and dry-binding agent	Widely used in direct compression and dry granulation
Povidone	Binder and granulation aid	Helps control granule strength and content uniformity
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup and immediate release
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and may reduce process variability
Lubricant	Reduces ejection force and sticking	Critical for high-speed tablet compression
Film-coating polymer	Protects the core and improves swallowability	Allows color coding and product differentiation
Colorants and opacifiers	Product identification and light protection	Support strength differentiation and brand recognition

Atogepant is administered at low tablet doses, particularly the 10 mg strength. Low-dose products create a higher content-uniformity burden because the active ingredient represents a smaller fraction of total tablet mass. Excipient selection and blending performance therefore have direct regulatory importance.

What excipient strategy is most relevant for atogepant?

The central excipient strategy is to maintain rapid and reproducible release while controlling low-dose content uniformity. A formulation developer should prioritize four performance attributes:

1. Uniform distribution of atogepant throughout the blend.
2. Rapid disintegration across tablet strengths.
3. Low sensitivity to humidity and lubricant overmixing.
4. Adequate tablet strength without excessive compression force.

Atogepant formulation work may require careful control of particle size, surface area, electrostatic behavior, and segregation tendency. A high-shear granulation process could improve uniformity but add drying, scale-up, and residual-moisture risks. Direct compression could reduce process steps, but it would place greater demands on powder flow and segregation control.

Which excipients create the strongest formulation opportunities?

Co-processed excipients

Co-processed microcrystalline cellulose, mannitol, starch, or silica systems could improve flow and compactability while reducing formulation complexity. A supplier that demonstrates equivalent or superior tablet performance at lower compression force could target both innovator lifecycle management and generic manufacturing.

Direct-compression grades

Specialized directly compressible mannitol and microcrystalline cellulose grades have commercial potential where the formulation must accommodate low drug loading. The value proposition is reduced granulation, improved throughput, and lower process water exposure.

Superdisintegrants

Sodium starch glycolate, crospovidone, and croscarmellose sodium could be evaluated as alternatives or complements. The selection should be based on disintegration time, dissolution profile, tablet hardness, and sensitivity to compression force. A formulation that disintegrates rapidly without excessive swelling may be preferable for patient acceptability and manufacturing robustness.

Low-moisture excipients

Moisture-controlled excipients may reduce chemical or physical instability during storage. Suppliers with tight loss-on-drying specifications, low bioburden, and consistent particle morphology can differentiate in regulated solid-dose manufacturing.

Lubricant systems

Magnesium stearate is common but can cause dissolution changes when overmixed or used at excessive concentration. Sodium stearyl fumarate and other lubricant systems may provide an alternative where dissolution, ejection force, or sensitivity to blending time becomes a development issue.

Film-coating systems

A ready-to-use aqueous film-coating system could simplify scale-up and improve color uniformity. Commercial value may arise from low-temperature processing, reduced coating time, improved opacity, and lower risk of tablet picking or logo bridging.

What formulation patents may protect QULIPTA or competing atogepant products?

QULIPTA protection may include several patent categories:

• Atogepant composition-of-matter patents
• Pharmaceutical composition patents
• Solid-state or crystalline-form patents
• Dosage and treatment-method patents
• Formulation and release-profile patents
• Manufacturing-process patents
• Combination-use patents

The formulation itself may be less commercially important than the underlying compound and method-of-use estate. For a generic manufacturer, the relevant risk is not limited to whether a tablet uses the same excipients. A substantially different formulation can still infringe a composition, dosage, treatment-method, or process claim.

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with the reference product.[4] Patent numbers, expiry dates, pediatric extensions, and listing status should be assessed from the current Orange Book entry and relevant USPTO records. Patent expiry does not necessarily equal immediate generic entry because litigation, settlements, pediatric extensions, regulatory review, and manufacturing readiness can alter the commercial launch date.

When does QULIPTA lose regulatory exclusivity?

QULIPTA received five-year new chemical entity exclusivity from its 2021 approval date. The standard NCE period generally prevents submission of an ANDA for four years and approval of an ANDA for five years, subject to statutory exceptions and applicable patent challenges.[5]

Milestone	Approximate date
FDA approval	September 28, 2021
Four-year ANDA submission restriction	September 28, 2025
Five-year NCE exclusivity endpoint	September 28, 2026
Earliest ordinary ANDA approval absent patent barriers	September 28, 2026

The actual generic launch date may occur later if listed patents remain enforceable, a Paragraph IV lawsuit triggers a 30-month stay, or a settlement establishes a later entry date.

What Paragraph IV risks exist for QULIPTA?

After the four-year NCE submission restriction, a generic applicant may submit an ANDA containing a Paragraph IV certification against listed patents. The applicant must notify AbbVie and patent owners. A timely patent-infringement suit can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework.[5]

Potential Paragraph IV strategies include:

• Challenging an atogepant composition patent.
• Arguing that formulation claims are invalid or not infringed.
• Designing a formulation around claimed excipients or process limitations.
• Challenging method-of-use claims through a skinny-label strategy.
• Contesting patent listing eligibility in the Orange Book.
• Pursuing a declaratory judgment if litigation is not initiated after notice.

For QULIPTA, a generic applicant would likely face a layered risk profile. Even if a formulation patent can be designed around, composition and method-of-use patents may remain relevant. The economics will depend on the number of competing filers, potential 180-day first-filer exclusivity, estimated litigation cost, and the value of entering before other oral CGRP products face generic pressure.

What generic launch scenarios exist for QULIPTA?

Scenario 1: First-filer launch after patent resolution

A first Paragraph IV filer could obtain 180-day exclusivity if statutory conditions are satisfied. This would delay other ANDA approvals and create a temporary period of limited generic competition.

Scenario 2: Authorized generic or settlement entry

AbbVie could resolve litigation through a settlement permitting a generic launch before patent expiry. The commercial terms could include a fixed entry date, restrictions on authorized-generic competition, or no-admission provisions.

Scenario 3: Non-infringing formulation with delayed launch

A company could develop an ANDA that avoids selected formulation claims but waits for composition or method patents to expire. This approach reduces litigation exposure but sacrifices early market entry.

Scenario 4: Skinny-label entry

If certain migraine indications or dosing regimens are protected by method-of-use claims, a generic sponsor could omit the protected use from its labeling. The practical value depends on prescribing behavior, pharmacy substitution, payer policy, and the scope of induced-infringement risk.

How strong is the QULIPTA patent estate?

QULIPTA has a stronger commercial position than a product protected only by a short-lived formulation patent because its risk profile may include compound, use, dosage, and formulation claims. The most valuable claims are those that block substitution across the principal marketed strengths and indications.

Patent strength should be assessed against five factors:

Factor	Assessment
Compound protection	Potentially high value because it covers the active ingredient broadly
Formulation protection	Important if it captures the commercial tablet platform
Method-of-use protection	Relevant to episodic and chronic migraine indications
Design-around potential	Moderate for excipient and process claims; lower for compound claims
Litigation exposure	Likely to increase as the NCE period ends and ANDA filings become available

Excipient suppliers should not assume that a non-infringing excipient substitution eliminates all patent exposure. The supplier’s opportunity is strongest where its product improves manufacturability without copying a claimed composition or process.

What FDA regulatory status applies to QULIPTA excipient changes?

A change to the QULIPTA formulation would be assessed under FDA postapproval change requirements. The regulatory filing could range from a minor notification to a prior-approval supplement, depending on the change and its impact on product quality.[6]

Relevant regulatory considerations include:

• Comparative dissolution across all strengths.
• Assay and content uniformity.
• Tablet hardness and friability.
• Disintegration time.
• Stability under long-term and accelerated conditions.
• Residual solvents and elemental impurities.
• Excipient safety and compendial status.
• Microbial quality for aqueous coating systems.
• Bioequivalence if the change could affect exposure.
• Supplier qualification and change-control commitments.

For a generic applicant, excipient selection must also comply with ANDA sameness requirements and the inactive-ingredient provisions applicable to the route and dosage form. An alternative excipient may be acceptable, but it can create additional justification, safety review, or bioequivalence work.

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities are not limited to selling the same excipient used in QULIPTA. Suppliers can create value through performance and regulatory support.

High-priority opportunities

Opportunity	Customer	Commercial rationale
Direct-compression mannitol or MCC	AbbVie, generic developers, CDMOs	Supports low-dose tablet manufacture
High-performance superdisintegrant	Formulators and generic sponsors	Protects rapid disintegration and dissolution
Co-processed excipient platform	Innovators and generics	Reduces process steps and improves flow
Low-moisture excipient system	Innovator and CDMO supply chains	Improves stability and process consistency
Ready-to-use film coating	Tablet manufacturers	Reduces coating development and scale-up time
Lubricant alternative	Generic developers	Addresses dissolution and ejection-force issues
Taste-masking system	Lifecycle-management teams	Enables chewable, dispersible, or pediatric products
Pediatric-friendly dosage form	AbbVie or 505(b)(2) sponsors	Expands use beyond standard adult tablets
Analytical and formulation services	CDMOs and patent challengers	Supports reverse engineering and bioequivalence programs

The highest-value opportunity is a multifunctional excipient system that improves content uniformity, flow, compression, and disintegration in one platform. Such a system can command a premium if supported by comparative data, regulatory documentation, and reliable global supply.

What alternative dosage forms could extend QULIPTA’s commercial life?

QULIPTA is currently positioned as a conventional tablet, but atogepant may support lifecycle opportunities in other oral formats if development work confirms acceptable exposure and stability.

Potential formats include:

• Orally disintegrating tablets
• Chewable tablets
• Powder for oral suspension
• Oral granules or sachets
• Smaller tablets for patients with swallowing difficulty
• Pediatric or adolescent formulations
• Strength combinations or flexible-dose platforms

An orally disintegrating or chewable formulation would compete more directly with Nurtec ODT and could improve adherence for patients who have nausea during migraine episodes. Such products could require taste masking, saliva-compatible disintegration, low friability, and packaging protection against humidity.

A new dosage form could support a 505(b)(2) strategy if the sponsor relies partly on FDA findings for atogepant while generating new data for the modified formulation.[7] Patent protection could then focus on the new dosage form, taste-masking system, particle engineering, or dosing regimen.

How does QULIPTA compare with competing migraine drugs?

Product	Active ingredient	Form	Preventive use	Excipient opportunity
QULIPTA	Atogepant	Once-daily tablet	Episodic and chronic migraine	Low-dose tablet, ODT, pediatric delivery
Nurtec ODT	Rimegepant	Orally disintegrating tablet	Acute and preventive use	Taste masking and fast disintegration
Ubrelvy	Ubrogepant	Tablet	Acute treatment	Conventional solid-dose optimization
Aimovig	Erenumab	Injection	Preventive use	Biologic formulation and device excipients
Ajovy	Fremanezumab	Injection	Preventive use	Injectable biologic excipient systems
Emgality	Galcanezumab	Injection	Preventive use	Biologic stability and prefilled-device systems

QULIPTA’s principal formulation advantage is convenience without injection-device requirements. Its principal formulation vulnerability is that tablet substitution is technically easier for generic competitors than biosimilar substitution for injectable antibodies.

What manufacturing and intellectual-property barriers affect suppliers?

The manufacturing barriers are moderate rather than extreme. Atogepant tablets do not require biologic cell culture, aseptic filling, or complex device assembly. The main technical barriers are low-dose uniformity, dissolution control, scale-up reproducibility, and stability.

Important intellectual-property barriers may include:

• Claimed excipient ranges.
• Specific ratios of disintegrant, binder, and diluent.
• Particle-size limitations.
• Solid-state or crystalline-form claims.
• Coating compositions.
• Process parameters such as granulation or drying.
• Treatment claims linked to migraine subtype or dosing frequency.

A supplier should perform a freedom-to-operate review before commercializing a platform expressly positioned as a QULIPTA substitute. A neutral positioning based on performance, compendial compliance, and multi-product use can reduce dependence on one brand and broaden the customer base.

What is the outlook for QULIPTA excipient demand?

Demand should remain strongest through the remaining branded-growth period and the initial generic-development cycle. Branded demand supports premium-grade excipients, while future generic competition shifts volume toward cost-efficient, validated, and globally available grades.

The commercial outlook divides into three phases:

Phase	Main demand driver	Best opportunity
Brand expansion	Increasing tablet volume and additional patients	Supply reliability and process optimization
Pre-generic development	Reverse engineering and bioequivalence programs	Generic-ready excipient systems and CDMO services
Generic competition	Price pressure and multiple manufacturers	Cost-efficient co-processed excipients and dual sourcing

Key Takeaways

• QULIPTA is a high-value oral CGRP product with reported 2024 sales of about $1.4 billion.
• Its immediate-release tablets rely on conventional excipient classes, including mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, colloidal silicon dioxide, lubricants, and film-coating materials.
• The most important formulation challenge is low-dose content uniformity combined with rapid and reproducible dissolution.
• Co-processed excipients, direct-compression grades, low-moisture systems, superdisintegrants, lubricant alternatives, and ready-to-use coatings offer the clearest commercial opportunities.
• QULIPTA received five-year NCE exclusivity from September 2021, with the ordinary NCE approval restriction extending to September 2026.
• Generic risk is meaningful because QULIPTA is a small molecule and does not face biosimilar substitution barriers.
• Alternative dosage forms, particularly orally disintegrating, chewable, and pediatric-friendly products, could support lifecycle management.
• The current FDA Orange Book and USPTO records should control any definitive assessment of listed patents, expiry dates, and Paragraph IV litigation exposure.
• Excipient suppliers with regulatory documentation, comparative dissolution data, and global manufacturing capacity will have a stronger position than commodity suppliers.

FAQs

Can a generic QULIPTA use different excipients?

Yes. An ANDA applicant may use different inactive ingredients when the formulation satisfies applicable FDA requirements, remains pharmaceutically equivalent, and demonstrates suitable quality and bioequivalence. Alternative excipients do not eliminate possible infringement of compound, method, formulation, or process patents.

Is QULIPTA an extended-release formulation?

No. QULIPTA is marketed as an immediate-release tablet. Its formulation strategy therefore emphasizes rapid disintegration, dissolution, content uniformity, and tablet robustness rather than extended-release matrix control.

Could atogepant be developed as an orally disintegrating tablet?

Yes, an orally disintegrating atogepant product is technically plausible. Development would require evaluation of taste masking, moisture protection, mechanical strength, disintegration, dissolution, and exposure relative to the approved tablet.

Does QULIPTA face biosimilar competition?

No. Atogepant is a small molecule. Any future competition would generally proceed through the generic drug pathway rather than the biosimilar pathway.

Which excipient suppliers are best positioned for QULIPTA-related opportunities?

Suppliers with high-functionality mannitol, microcrystalline cellulose, co-processed excipients, superdisintegrants, moisture-controlled grades, film-coating systems, and regulatory change-control support are best positioned. CDMOs that can develop low-dose tablets and execute comparative dissolution and stability programs also have a commercial advantage.

References

1. U.S. Food and Drug Administration. (2024). QULIPTA (atogepant) prescribing information.
2. U.S. Food and Drug Administration. (2023). FDA approves new indication for QULIPTA for preventive treatment of chronic migraine.
3. AbbVie Inc. (2025). 2024 annual report.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards.
6. U.S. Food and Drug Administration. (2004). Changes to an approved NDA or ANDA: Guidance for industry.
7. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2): Guidance for industry.